Chardan’s Top Pick For 2018: Gene Therapy Firm Uniqure – Benzinga
Benzinga |
Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure
Benzinga Amusa expects uniQure, with a scaled manufacturing process, to beat Spark Therapeutics Inc (NASDAQ: ONCE) to market with its AAV-based hemophilia B gene therapy. Hemophilia B presents a market opportunity north of $15 billion, and Amusa anticipates a … |
